Sparks - Cereno Scientific

Cereno Scientific has presented encouraging new preclinical data for CS585, a novel prostacyclin (IP) receptor agonist, showcasing its ability to inhibit platelet activation and clot formation in the blood up to 24 hours after administration. These sustained effects were observed in both in vivo and ex vivo models, making it a promising candidate for thrombotic diseases with the potential to differentiate from current FDA-approved IP receptor agonists. As CS585 is in the early stages of development, a precise indication is yet to be determined, though an announcement regarding this selection is expected by end-2024. Cereno’s two other assets are in the clinical stages of development. CS014, a histone deacetylase (HDAC) inhibitor designed for thrombosis prevention without increased risk of bleeding, recently entered a first-in-human Phase I trial; initial data are expected from mid-2025. Lead asset CS1, a HDAC inhibitor being developed as a potential treatment for pulmonary arterial hypertension, is nearing the end of a Phase II trial; top-line results are expected within September 2024.